ENHERTU (trastuzumab deruxtecan)
HER2 Positive Early Breast Cancer (Post-Neoadjuvant)
Key Facts
Indication
HER2 Positive Early Breast Cancer (Post-Neoadjuvant)
Phase
Regulatory Review
Status
Priority Review (PDUFA July 7, 2026)
Company
About Daiichi Sankyo
Daiichi Sankyo has successfully pivoted from a traditional pharmaceutical company to a global oncology leader, anchored by its groundbreaking DXd ADC technology platform. Its flagship drug, ENHERTU, developed in partnership with AstraZeneca, has achieved multi-billion dollar sales and is expanding into earlier lines of therapy across multiple HER2-expressing cancers. The company's strategy focuses on leveraging its platform to build a deep, diversified pipeline targeting HER2, TROP2, and other tumor antigens, aiming to become a world-leading oncology company by 2030.
View full company profile